In patients receiving tenofovir disoproxil, rare events of renal impairment, renal failure and proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have been reported. Monitoring of renal function is recommended for patients receiving Lamivudine/Tenofovir Disoproxil Fumarate 300 mg/300 mg Tablets (see Precautions).
Co-administration of tenofovir disoproxil and didanosine is not recommended as this may result in an increased risk of adverse reactions (see Drug Interactions). Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported (see Precautions).
Discontinuation of Lamivudine/Tenofovir Disoproxil Fumarate 300 mg/300 mg Tablets therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see Precautions).
The adverse events considered at least possibly related to treatment with the components of Lamivudine/Tenofovir Disoproxil Fumarate 300 mg/300 mg Tablets are listed as follows by body system, organ class and frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (≥ 1 in 10), common (1 in 100 to 1 in 10), uncommon (1 in 1000 to 1 in 100), rare (1 in 10000 to 1 in 1000), very rare (≤ 1 in 10 000), and 'unknown' (frequency cannot be estimated from the available data).
Blood and lymphatic systems disorders: Uncommon: neutropenia, anaemia (occasionally severe), thrombocytopenia. Very rare: pure red cell aplasia.
Metabolism and nutrition disorders: Very common: hypophosphataemia. Rare: lactic acidosis. Not known: hypokalaemia.
Nervous system disorders: Very common: dizziness. Common: headache and insomnia. Very rare: peripheral neuropathy (paraesthesia).
Respiratory, thoracic and mediastinal disorders: Common: cough, nasal symptoms. Very rare: Dyspnoea.
Gastrointestinal disorders: Very common: diarrhoea, nausea, vomiting. Common abdominal pain/cramps, flatulence. Rare: pancreatitis, elevated serum amylases.
Hepatobiliary disorders: Uncommon transient elevation in liver enzymes. Rare: hepatitis. Not known: hepatic steatosis.
Skin and subcutaneous tissue disorders: Common rash, hair loss.
Musculoskeletal and connective tissue disorders: Common: arthralgia, muscle disorder. Not known: rhabdomyolysis, osteomalacia (manifested as bone pain and infrequently contributing to fractures), muscular weakness, myopathy, osteonecrosis.
Renal and urinary disorders: Rare: acute renal failure, renal failure, proximal renal tubulopathy (including Fanconi syndrome), increased serum creatinine. Very rare: acute tubular necrosis. Not known: nephritis (including acute interstitial nephritis), nephrogenic diabetes insipidus.
General disorders and administration site disorders: Common fatigue, malaise, fever. Very rare: asthenia. Not known: immune reconstitution syndrome.
The following adverse reactions, listed previously, may occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia (as bone pain and infrequently contributing to fractures), hypokalaemia, muscular weakness, myopathy and hypophosphataemia. These events are not considered to be caused by tenofovir disoproxil in the absence of proximal renal tubulopathy. In HBV infected patients, exacerbations of hepatitis have occurred after discontinuation of HBV therapy (see Precautions).
Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see Precautions).
Pre-exposure prophylaxis: In two randomised controlled HIV-prevention trials in men who have sex with men, transgender women (iPrEx trial) and serodiscordant couples (Partners PrEP), in which 2830 uninfected adults received fixed dose combination tablets of emtricitabine* and tenofovir disoproxil fumarate no new adverse reactions were reported. Of those reactions, occurring in at least 2% of subjects, the following were reported more frequently in the treatment group (as compared to placebo, all from iPrEx-trial).
Headache (7% vs. 6%), Syphilis (6% vs. 5%), Secondary syphilis (6% vs. 4%), Abdominal pain (4% versus 2%) & Weight decreased (3% vs, 2%).
The following laboratory abnormalities were reported in these trials. (See Table 1.)
Click on icon to see table/diagram/image
In addition to the laboratory abnormalities described previously, grade 1 proteinuria occurred in 6% of subjects receiving emtricitabine*/tenofovir disoproxil fumarate in the iPrEx trial. Grades 2 proteinuria and glycosuria occurred in less than 1% of subjects treated with emtricitabine*/tenofovir disoproxil fumarate in the iPrEx trial and Partners PrEP trial.
Six subjects in the tenofovir-containing arms of the Partners PrEP trial discontinued participation in the study due to an increase in blood creatinine compared with no discontinuations in the placebo group. One subject in the emtricitabine*/tenofovir disoproxil arm of the iPrEx trial discontinued from the study due to an increase in blood creatinine and another due to low phosphorous.
Changes in Bone Mineral Density (BMD): In clinical trials of HIV-1 uninfected individuals, decreases in BMD were observed. In the iPrEx trial, a substudy of 503 subjects found mean changes from baseline in BMD ranging from -0.4% to -1.0% across total hip, spine, femoral neck, and trochanter in the emtricitabine*/tenofovir disoproxil fumarate group compared with the placebo group, which returned toward baseline after discontinuation of treatment. Thirteen percent of subjects receiving emtricitabine*/tenofovir disoproxil fumarate vs. 6% of subjects receiving placebo lost at least 5% of BMD at the spine during treatment. Bone fractures were reported in 1.7% of the emtricitabine*/tenofovir disoproxil fumarate group compared with 1.4% in the placebo group. No correlation between BMD and fractures was noted (see Overdosage). The Partners PrEP trial found similar fracture rates between treatment and placebo groups (0.8% and 0.6%, respectively).
No BMD evaluations were conducted during this trial.
Description of selected adverse reactions: Renal toxicity: As Lamivudine/Tenofovir Disoproxil Fumarate 300 mg/300 mg Tablets may cause renal damage, monitoring of renal function is recommended (see Precautions and Adverse Reactions). Proximal renal tubulopathy generally resolved or improved after tenofovir disoproxil discontinuation. However, in some patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation. Patients at risk of renal impairment (such as patients with baseline renal risk factors, advanced HIV disease, or patients receiving concomitant nephrotoxic medications) are at increased risk of experiencing incomplete recovery of renal function despite tenofovir disoproxil discontinuation (see Precautions).
The following adverse reactions, listed under the body system headings as mentioned previously, may occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia (manifested as bone pain and infrequently contributing to fractures), hypokalaemia, muscular weakness, myopathy and hypophosphataemia. These events are not likely to be causally associated with tenofovir disoproxil therapy in the absence of proximal renal tubulopathy.
Interaction with didanosine: Co-administration of tenofovir disoproxil and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see Interactions). Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported.
Metabolic parameters: Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see Precautions).
Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves' disease) have also been reported; the reported time to onset is more variable and these events can occur many months after initiation of treatment (see Precautions).
Osteonecrosis: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see Precautions).
Paediatric population: Safety data from studies using the combination tablet in patients less than 10 years of age are not available. In studies with emtricitabine* in addition to the adverse reactions reported in adults, the following adverse reactions were observed more frequently in paediatric patients: anaemia was common (9.5%) and skin discolouration (increased pigmentation) was very common (31.8%). The adverse reactions observed in paediatric patients who received treatment with tenofovir disoproxil or lamivudine as single entities were consistent with those observed in clinical studies in adults.
Other special population(s): Elderly: Lamivudine/tenofovir disoproxil has not been studied in patients over the age of 65. Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with emtricitabine*/tenofovir disoproxil.
HIV/HBV or HCV co-infected patients: Limited data on patients co-infected with HIV/HBV or HIV/HCV indicate that the adverse reaction profile of emtricitabine* and tenofovir disoproxil in patients co-infected with HIV/HBV or HIV/HCV was similar to that observed in patients infected with HIV without co-infection. However, as would be expected, elevations in AST and ALT occurred more frequently than in the general HIV infected population.
In HIV-negative individuals limited data indicate that the adverse reaction profile of emtricitabine* and tenofovir disoproxil was similar in individuals with and without hepatitis B/C infection.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the local reporting system.